An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Moderate to severe rheumatoid arthritis * Patients for whom the treating physician has made the decision to commence RoActemra/Actemra treatment. In Group A RoActemra/Actemra has been prescribed within 8 weeks prior to the enrolment visit. In Group B RoActemra/Actemra has been started more than 8 weeks before inclusion in the study, but not before January 2011 Exclusion Criteria: * RoActemra/Actemra treatment more than 8 weeks prior to inclusion visit for Group A, before January 2011 for Group B * Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use * Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra * History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis